SELL and cervical cancer: In cDC panels, CD123 on plasmacytoid Dendritic Cell (OR=2.48, 95%CI:1.229-5.003, P=0.011), CD123 on CD62L+ plasmacytoid Dendritic Cell (OR=2.5, 95%CI:1.231-5.077, P=0.011), CD80 on plasmacytoid Dendritic Cell (OR=2.62, 95%CI:1.244-5.515, P=0.011), CD80 on CD62L+ plasmacytoid Dendritic Cell (OR=2.641, 95%CI:1.246-5.596, P=0.011) had a disadvantageous association with cervical cancer(Table 2, Figure 2B).